A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Richard D. | - |
dc.contributor.author | Chung, Vincent | - |
dc.contributor.author | Alese, Olatunji B. | - |
dc.contributor.author | El-Rayes, Bassell F. | - |
dc.contributor.author | Li, Daneng | - |
dc.contributor.author | Al-Toubah, Taymeyah E. | - |
dc.contributor.author | Schell, Michael J. | - |
dc.contributor.author | Zhou, Jun-Min | - |
dc.contributor.author | Mahipal, Amit | - |
dc.contributor.author | Kim, Baek Hui | - |
dc.contributor.author | Kim, Dae Won | - |
dc.date.accessioned | 2021-08-30T22:52:22Z | - |
dc.date.available | 2021-08-30T22:52:22Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 2374-2437 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/55608 | - |
dc.description.abstract | This multicenter phase 2 study evaluates the anticancer activity of nivolumab in patients with advanced refractory biliary tract cancer. Question What is the clinical activity of nivolumab in patients with advanced refractory biliary tract cancer? Findings In this multicenter phase 2 study of 54 patients with advanced refractory biliary tract cancer, 10 patients achieved an objective response with a disease control rate of 59% by investigator assessment. Five patients experienced an objective response with a disease control rate of 50% by blinded central independent radiologic review. Meaning Further exploration of nivolumab is warranted for patients with advanced refractory biliary tract cancer. IMPORTANCE Currently, there is no established second-line systemic treatment for biliary tract cancer (BTC). Preclinical data have demonstrated that the presence of tumor-infiltrating CD8 T cells and programmed cell death 1 ligand 1-expressing tumor cells in the tumor microenvironment of BTC supports the rationale of using programmed cell death 1 protein blockade immunotherapy in BTC. OBJECTIVE To evaluate anticancer activity of nivolumab in patients with advanced refractory BTC. DESIGN, SETTING, AND PARTICIPANTS In this single-group, multicenter phase 2 study of nivolumab, 54 patients with histologically confirmed BTC whose disease progressed while undergoing treatment with at least 1 line but no more than 3 lines of systemic therapy were enrolled between October 5, 2016, and December 26, 2018. Analysis was performed on an intention-to-treat basis. INTERVENTIONS Nivolumab, 240 mg, was delivered intravenously every 2 weeks for 16 weeks, and then 480 mg was delivered intravenously every 4 weeks until disease progression or unacceptable toxic effects occurred. MAIN OUTCOMES AND MEASURES The primary end point was investigator-assessed objective response rate, and the secondary end points were progression-free survival, overall survival, and incidence of adverse events. RESULTS A total of 54 patients (27 men and 27 women; median age, 65 years [range, 28-86 years]) enrolled, and 46 (22 men and 24 women; median age, 65 years [range, 28-86 years]) were examined for objective response with radiologic imaging. The investigator-assessed objective response rate was 22% (10 of 46), including 1 unconfirmed partial response, with a disease control rate of 59% (27 of 46). Central independent review found an objective response rate of 11% (5 of 46), including 1 unconfirmed partial response, with a disease control rate of 50% (23 of 46). All patients who responded to treated (hereafter referred to as responders) had mismatch repair protein-proficient tumors. The median duration of investigator-assessed response was not reached, with a median follow-up of 12.4 months. Among the intention-to-treat population, median progression-free survival was 3.68 months (95% CI, 2.30-5.69 months) and median overall survival was 14.24 months (95% CI, 5.98 months to not reached). Programmed cell death 1 ligand 1 expression in tumors was associated with prolonged progression-free survival (hazard ratio, 0.23; 95% CI, 0.10-0.51; P < .001). The most common treatment-related grade 3 or 4 toxic effects were hyponatremia (3 of 54 [6%]) and increased alkaline phosphatase (2 of 54 [4%]). CONCLUSIONS AND RELEVANCE This study found that nivolumab was well tolerated and showed modest efficacy with durable response in patients with refractory BTC. Further studies are warranted to verify the findings and evaluate biomarkers for improved treatment selection for patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AMER MEDICAL ASSOC | - |
dc.subject | SOLID TUMORS | - |
dc.subject | PD-1 | - |
dc.subject | EXPRESSION | - |
dc.subject | PROGNOSIS | - |
dc.subject | CRITERIA | - |
dc.title | A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Baek Hui | - |
dc.identifier.doi | 10.1001/jamaoncol.2020.0930 | - |
dc.identifier.scopusid | 2-s2.0-85084643772 | - |
dc.identifier.wosid | 000542037700014 | - |
dc.identifier.bibliographicCitation | JAMA ONCOLOGY, v.6, no.6, pp.888 - 894 | - |
dc.relation.isPartOf | JAMA ONCOLOGY | - |
dc.citation.title | JAMA ONCOLOGY | - |
dc.citation.volume | 6 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 888 | - |
dc.citation.endPage | 894 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | SOLID TUMORS | - |
dc.subject.keywordPlus | PD-1 | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | CRITERIA | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.